News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene Corporation (CELG) Drug Revlimid Increases Risk of Certain New Cancers


5/8/2012 7:45:37 AM

The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. Revlimid is approved to treat patients with multiple myeloma, a bone-marrow cancer in combination with another drug. The product is also approved to treat another bone-marrow condition called myelodysplastic syndromes. In a drug-safety communication posted to the FDA's website Monday, the agency said data from clinical trials of Revlimid showed newly diagnosed patients treated with Revlimid had an increased risk of developing second types of cancer compared to similar patients who received a placebo, or fake drug.

Read at Fox News
Read at News Release
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES